Publications
Research SquareOct 2023 DOI:
10.21203/rs.3.rs-3329019/v1

Engineering of extracellular vesicles for efficient intracellular delivery of multimodal therapeutics including genome editors

Liang, Xiuming; Gupta, Dhanu; Xie, Junhua; Wonterghem, Elien; Hoecke, Lien; Hean, Justin; Niu, Zheyu; Wiklander, Oscar; Zheng, Wenyi; Wiklander, Rim; He, Rui; Mammad, Doste; Bost, Jeremy; Zhou, Guannan; Zhou, Houze; Roudi, Samantha; Zickler, Antje; Gorgens, Andre; Hagey, Daniel; de Jong, Olivier G; Uy, Aileen; Zong, Yuanyuan; Mager, Imre; Perez, Carla; Roberts, Thomas; Vader, Pieter; Fougerolles, Antonin; Wood, Matthew; Vandenbroucke, Roosmarijn; Nordin, Joel; El-Andaloussi, Samir
Product Used
Genes
Abstract
Intracellular delivery of protein and RNA therapeutics represents a major challenge. Here, we developed highly potent engineered extracellular vesicles (EVs) by incorporating essential bio-inspired attributes required for effective delivery. These comprise engineered mini-intein proteins with self-cleavage activity for active cargo loading and release, and fusogenic VSV-G protein to activate productive endosomal escape. Combining these components allowed high efficiency recombination and genome editing in vitrofollowing EV-mediated delivery of Cre recombinase and Cas9/sgRNA RNP cargoes, respectively. In vivo, single dose EV-mediated Cre delivery to the brains of Cre-LoxP R26-LSL-tdTomato reporter mice resulted in greater than 40% and 30% recombined cells in hippocampus and cortex respectively. In addition, we demonstrate therapeutic potential of this platform by showing inhibition of LPS-induced systemic inflammation via delivery of a super-repressor of NF-ĸB activity. Our data establish these engineered EVs as a novel platform for effective delivery of multimodal therapeutic cargoes, including for efficient genome editing.
Product Used
Genes

Related Publications